logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation

Shandong Fengyuan Chemical (002805.SZ) the actual controller, Zhao Guanghui, has released a pledge of 23.8 million shares.

date
17:56 07/09/2023
avatar
GMT Eight
"Shandong Fengyuan Chemical (002805.SZ) announced that it has recently received a notification from its controlling shareholder and actual controller, Zhao Guanghui, stating that all of his pledged 23.80 million shares (8.50% of the company's total shares) have been released from the pledge."
Related Articles
HK Stock
WUXI XDC (02268) announces happy profit forecast, with expected annual net profit increase of over 38% in 2025.
HK Stock
LEADS BIOLABS-B (09887): Veltisim (PD-L1/4-1BB bispecific antibody Optatisomab monoclonal antibody, LBL-024) has been granted fast track designation by the US FDA.
HK Stock
ANCHORSTONE (01592) plans to increase its authorized capital to HK$400 million, with a discount of approximately 42.86%, by issuing new shares on a "1 for 4" basis.
WUXI XDC (02268) announces happy profit forecast, with expected annual net profit increase of over 38% in 2025.
HK Stock
LEADS BIOLABS-B (09887): Veltisim (PD-L1/4-1BB bispecific antibody Optatisomab monoclonal antibody, LBL-024) has been granted fast track designation by the US FDA.
HK Stock
ANCHORSTONE (01592) plans to increase its authorized capital to HK$400 million, with a discount of approximately 42.86%, by issuing new shares on a "1 for 4" basis.
HK Stock
RECOMMEND
Wall Street Alert: Trump’s Confrontation With The Fed Could Elevate Rates And Threaten Market Stability
Wall Street Alert: Trump’s Confrontation With The Fed Could Elevate Rates And Threaten Market Stability
icon
14/01/2026
Dual Large‑Model Leaders Propel Hong Kong Stocks Higher As AI Applications Diversify
Dual Large‑Model Leaders Propel Hong Kong Stocks Higher As AI Applications Diversify
icon
14/01/2026
A‑Shares Open The Year With Consecutive Gains While Hong Kong Stocks Lag
A‑Shares Open The Year With Consecutive Gains While Hong Kong Stocks Lag
icon
14/01/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.